Erste Asset Management GmbH Grows Stake in Sarepta Therapeutics, Inc. $SRPT

Erste Asset Management GmbH grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.6% during the fourth quarter, HoldingsChannel reports. The fund owned 2,728,945 shares of the biotechnology company’s stock after purchasing an additional 43,000 shares during the period. Erste Asset Management GmbH’s holdings in Sarepta Therapeutics were worth $58,727,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. WINTON GROUP Ltd purchased a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $243,000. State of Wyoming purchased a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $150,000. Sivia Capital Partners LLC purchased a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $282,000. Westpac Banking Corp purchased a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $154,000. Finally, AXQ Capital LP increased its holdings in shares of Sarepta Therapeutics by 38.5% in the 4th quarter. AXQ Capital LP now owns 20,247 shares of the biotechnology company’s stock valued at $436,000 after acquiring an additional 5,628 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In related news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director owned 1,765 shares in the company, valued at $30,040.30. This trade represents a 80.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 6.90% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

SRPT has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft increased their price objective on Sarepta Therapeutics from $12.00 to $14.00 and gave the company a “sell” rating in a report on Thursday, March 26th. Oppenheimer reiterated an “outperform” rating and issued a $37.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Loop Capital set a $25.00 price objective on Sarepta Therapeutics in a report on Tuesday, March 3rd. HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a report on Thursday, April 16th. Finally, Jefferies Financial Group restated a “buy” rating and set a $30.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 3rd. Eight analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Hold” and an average price target of $24.77.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $15.75 on Monday. The stock’s 50 day moving average price is $19.81 and its 200 day moving average price is $19.82. The company has a market capitalization of $1.66 billion, a PE ratio of -16.41, a P/E/G ratio of 0.17 and a beta of 0.21. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $43.92.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. The firm had revenue of $730.80 million for the quarter, compared to the consensus estimate of $474.16 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the business posted ($3.42) EPS. On average, research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.99 EPS for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.